Soleno Therapeutics, Inc. (SLNO) 股票分析

公司概述

Soleno Therapeutics, Inc. operates as a biopharmaceutical entity dedicated to the development and commercialization of novel therapeutics specifically designed for the treatment of rare diseases. Within the broader Healthcare sector, the company functions in the specialized Biotechnology industry, focusing on high-value, low-prevalence disease states that often require distinct regulatory and commercial strategies. The firm currently maintains a substantial market capitalization of $2.72B while employing a workforce of 182 individuals, with annual revenue reaching $190.40M over the trailing twelve-month period. These financial metrics indicate a significant operational scale for a biotechnology firm focused on rare diseases, suggesting established commercialization capabilities that extend beyond early-stage research and development phases.

财务健康

Over the trailing twelve months, the company reported revenue of $190.40M, net income of $20.48M, and EBITDA of $16.97M, revealing a cost structure where operating expenses are substantial yet managed to maintain profitability. The net income figure of $20.48M is lower than the EBITDA of $16.97M only in nominal terms if comparing direct figures, but more critically, the profit margin of 11.0% indicates that approximately nine cents of every dollar in revenue translates to bottom-line profit after all expenses, including interest and taxes, are accounted for. The company generated free cash flow of $48.27M, a figure that signifies strong financial flexibility to fund further R&D initiatives, manage clinical trial costs, or pursue strategic acquisitions without immediate reliance on external capital markets. Analyzing the three key margins, the gross margin stands at an exceptionally high 98.6%, reflecting the typical asset-light nature of biotechnology products where manufacturing costs are low relative to product pricing; the operating margin of 44.1% demonstrates efficient control over overhead and administrative expenses; and the profit margin of 11.0% confirms the company's ability to generate sustainable earnings despite the capital-intensive nature of drug development. Regarding capital structure, Soleno holds cash reserves of $305.47M against total debt of $52.55M, resulting in a debt-to-equity ratio of 11.68, which suggests a highly leveraged balance sheet by traditional banking standards but indicates a net cash position when liquidity is considered. This net cash position provides a conservative buffer against market volatility, although the high debt-to-equity ratio must be interpreted in the context of the company's cash on hand. The current ratio is recorded at 5.80, indicating that the company possesses 5.80 dollars of current assets for every dollar of current liabilities, which points to robust short-term liquidity and a strong ability to meet its obligations as they come due. Finally, the return on equity is 6.0% while the return on assets is 2.1%, metrics that reveal management effectiveness in generating profits from shareholder equity and utilizing total assets, respectively, with the disparity suggesting that significant assets may be held in low-yielding forms like cash or that the asset base is large relative to the equity.

估值评估

The trailing twelve-month P/E ratio is 134.87, while the forward P/E is -23.17, implying that the market expects earnings growth that could significantly alter the valuation multiple in the coming year, though the negative forward multiple suggests analysts anticipate a decline in earnings or a lack of consensus on future profitability in the immediate term. The price-to-book ratio is 6.11, indicating that the market values the company's equity at more than six times its book value, which reflects a high premium assigned to its intangible assets, proprietary drug candidates, and future commercial potential. Alternative valuation metrics such as the price-to-sales ratio of 14.29 and the EV/EBITDA of 145.14 suggest that investors are willing to pay a substantial multiple relative to revenue and earnings, typical for biotech firms with high-growth potential but not yet fully realized commercial success. The 52-week high is $90.32 and the 52-week low is $29.43, providing a historical trading range that contextualizes current price levels relative to recent volatility. The beta value is -2.81, a negative figure that indicates the stock's price moves inversely to the broader market with high volatility, meaning that when the market rises, this stock may fall, and vice versa, presenting unique risk characteristics compared to standard equities.

Growth & Income

The revenue growth and earnings growth rates are listed as N/A in the provided data, preventing a direct comparison of whether earnings are growing faster or slower than revenue, yet the absence of year-over-year growth figures in the source data suggests that the company may be in a transition phase or that the specific growth metrics are not yet standardized for reporting. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, Soleno reinvests its earnings entirely back into the business to fund research, development, and commercialization efforts rather than distributing cash to shareholders. This reinvestment strategy is common for biotechnology companies in the Soleno Therapeutics, Inc. business model, where capital allocation toward product pipelines is prioritized over income generation for current investors. The overall growth and income profile is characterized by a focus on capital appreciation and pipeline development rather than current yield, with the company relying on the successful commercialization of its lead product candidates, such as VYKAT XR, to drive future financial expansion.